Long-Acting Injectable Antipsychotics-A Review on Formulation and In Vitro Dissolution

被引:15
作者
Markowicz-Piasecka, Magdalena [1 ]
Kubisiak, Marcin [2 ]
Asendrych-Wicik, Katarzyna [2 ,3 ]
Kolodziejczyk, Michal [4 ]
Grzelinska, Joanna [2 ]
Fabijanska, Malgorzata [5 ]
Pietrzak, Tomasz [2 ,6 ]
机构
[1] Med Univ Lodz, Dept Appl Pharm, Ul Muszynskiego 1, PL-90151 Lodz, Poland
[2] Polfa Warszawa SA, Res & Dev Dept, Liquid Dosage Form Lab, Karolkowa 22-24, PL-01207 Warsaw, Poland
[3] Med Univ Lodz, Dept Pharmaceut Chem Drug Anal & Radiopharm, Ul Muszynskiego 1, PL-90151 Lodz, Poland
[4] Med Univ Lodz, Dept Drug Form Technol, Ul Muszynskiego 1, PL-90151 Lodz, Poland
[5] Med Univ Lodz, Dept Bioinorgan Chem, Ul Muszynskiego 1, PL-90151 Lodz, Poland
[6] Warsaw Univ Technol, Fac Chem, Noakowskiego 3, PL-00664 Warsaw, Poland
关键词
neuroleptics; long-acting injectables (LAIs); in vitro drug release; in vitro-in vivo correlation (IVIVC); ARIPIPRAZOLE LAUROXIL; RELAPSE PREVENTION; RELEASE BEHAVIOR; DRUG-DELIVERY; SCHIZOPHRENIA; RISPERIDONE; PHARMACOKINETICS; FLOCCULATION; INJECTION; ZUCLOPENTHIXOL;
D O I
10.3390/pharmaceutics16010028
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Long-acting injectable (LAI) neuroleptics constitute an effective therapeutical alternative for individuals suffering from persistent mental illness. These injectable pharmaceuticals help patients manage their condition better and improve long-term outcomes by preventing relapses and improving compliance. This review aims to analyse the current formulation aspects of LAI neuroleptics, with particular emphasis on analysis of drug release profiles as a critical test to guarantee drug quality and relevant therapeutical activity. While there is no officially approved procedure for depot parenteral drug formulations, various dissolution tests which were developed by LAI manufacturers are described. In vitro dissolution tests also possess a critical function in the estimation of the in vivo performance of a drug formulation. For that reason, thorough inspection of the in vitro-in vivo correlation (IVIVC) is also discussed.
引用
收藏
页数:30
相关论文
共 161 条
[1]  
A, 2022, Clinical Pharmacology Trial of Brexpiprazole Long Acting Injectable (LAI) Administered as a Single Dose in Patients with Schizophrenia
[2]   Systematic meta-review of depot antipsychotic drugs for people with schizophrenia [J].
Adams, CE ;
Fenton, MKP ;
Quraishi, S ;
David, AS .
BRITISH JOURNAL OF PSYCHIATRY, 2001, 179 :290-299
[3]   Long-acting injectable antipsychotics in the treatment of schizophrenia: their role in relapse prevention [J].
Agid, Ofer ;
Foussias, George ;
Remington, Gary .
EXPERT OPINION ON PHARMACOTHERAPY, 2010, 11 (14) :2301-2317
[4]  
Ameer M.A., 2021, NEUROLEPTIC MEDICATI
[5]   Monthly Extended-Release Risperidone (RBP-7000) in the Treatment of Schizophrenia Results From the Phase 3 Program [J].
Andorn, Anne ;
Graham, Jay ;
Csernansky, John ;
Newcomer, John W. ;
Shinde, Sunita ;
Muma, Gilbert ;
Heidbreder, Christian ;
Fava, Maurizio .
JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY, 2019, 39 (05) :428-433
[6]  
[Anonymous], 1999, Specifications: test procedures and acceptance criteria for biotechnological/biological products
[7]  
[Anonymous], 2021, Product characteristics of Hydroxyzinum VP
[8]  
[Anonymous], 2010, AUSTR PUBLIC ASSESSM
[9]  
[Anonymous], 2023, Asimtufii: Withdrawal of the Marketing Authorisation Application
[10]  
[Anonymous], 2015, FDA Dissolution Methods Aripiprazole